Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 7
2003 5
2004 12
2005 7
2006 9
2007 14
2008 14
2009 12
2010 13
2011 16
2012 12
2013 10
2014 11
2015 7
2016 14
2017 9
2018 6
2019 8
2020 10
2021 19
2022 6
2023 7
2024 13
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Results by year

Filters applied: . Clear all
Page 1
The effects of vitrification on oocyte quality.
Chang CC, Shapiro DB, Nagy ZP. Chang CC, et al. Among authors: nagy zp. Biol Reprod. 2022 Feb 22;106(2):316-327. doi: 10.1093/biolre/ioab239. Biol Reprod. 2022. PMID: 34962575 Review.
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Salles G, et al. Among authors: nagy z. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5. Lancet Oncol. 2020. PMID: 32511983 Clinical Trial.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, Nagy Z, Tournilhac O, Kuffer C, Bakuli A, Amin A, Gurbanov K, Salles G. Duell J, et al. Among authors: nagy z. Haematologica. 2024 Feb 1;109(2):553-566. doi: 10.3324/haematol.2023.283480. Haematologica. 2024. PMID: 37646664 Free PMC article. Clinical Trial.
The role of transforming growth factor-beta in Marfan syndrome.
Benke K, Ágg B, Szilveszter B, Tarr F, Nagy ZB, Pólos M, Daróczi L, Merkely B, Szabolcs Z. Benke K, et al. Among authors: nagy zb. Cardiol J. 2013;20(3):227-34. doi: 10.5603/CJ.2013.0066. Cardiol J. 2013. PMID: 23788295 Free article. Review.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. Among authors: nagy z. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R. Röth A, et al. Among authors: nagy z. Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399. Blood. 2020. PMID: 31978221 Free PMC article. Clinical Trial.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Mateos MV, et al. Among authors: nagy z. Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10. Lancet. 2020. PMID: 31836199 Clinical Trial.
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
Scheinberg P, Clé DV, Kim JS, Nur E, Yenerel MN, Barcellini W, Bonito D, Giai V, Hus M, Lee Y, Lekue CB, Panse J, Ueda Y, Buatois S, Gentile B, Kiialainen A, Patel H, Sreckovic S, Uguen M, Edwards J, Nagy Z, Kulasekararaj AG. Scheinberg P, et al. Among authors: nagy z. Am J Hematol. 2024 Sep;99(9):1757-1767. doi: 10.1002/ajh.27413. Epub 2024 Jun 25. Am J Hematol. 2024. PMID: 38924124 Clinical Trial.
[Extraadrenal glucocorticoid synthesis].
Szappanos Á, Mészáros K, Nagy Z, Kövesdi A, Likó I, Kiss E, Tóth M, Patócs A. Szappanos Á, et al. Among authors: nagy z. Orv Hetil. 2018 Feb;159(7):260-268. doi: 10.1556/650.2018.31019. Orv Hetil. 2018. PMID: 29429352 Review. Hungarian.
221 results